Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Cardiovascular Research · 02.05.2023 · 119 (4) · 886-904
DOI: 10.1093/cvr/cvac112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 04.08.2022. Verfasst von Sten Madsbad und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Copenhagen 2630, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cardiovascular Diseases. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 173 Literaturangaben.
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to treat patients with type 2 diabetes since 2005 and have become popular because of the efficacy and durability in relation to glycaemic control in combination with weight loss in most patients. Today in 2022, seven GLP-1 RAs, including oral semaglutide are available for treatment of type 2 diabetes. Since the efficacy in relation to reduction of HbA1c and body weight as well as tolerability and dosing frequency vary between agents, the GLP-1 RAs cannot be considered equal. The short acting lixisenatide showed no cardiovascular benefits, while once daily liraglutide and the weekly agonists, subcutaneous semaglutide, dulaglutide, and efpeglenatide, all lowered the incidence of cardiovascular events. Liraglutide, oral semaglutide and exenatide once weekly also reduced mortality. GLP-1 RAs reduce the progression of diabetic kidney disease. In the 2019 consensus report from European Association for the Study of Diabetes/American Diabetes Association, GLP-1 RAs with demonstrated cardio-renal benefits (liraglutide, semaglutide and dulaglutide) are recommended after metformin to patients with established cardiovascular diseases or multiple cardiovascular risk factors. European Society of Cardiology suggests starting with a sodium-glucose cotransprter-2 inhibitor or a GLP-1 RA in drug naïve patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (CVD) or high CV Risk. However, the results from cardiovascular outcome trials (CVOT) are very heterogeneous suggesting that some GLP-1RAs are more suitable to prevent CVD than others. The CVOTs provide a basis upon which individual treatment decisions for patients with T2D and CVD can be made.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Copenhagen 2630, Denmark.
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark.
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark.
ORCID-Profile: Jens J Holst
Zitieren
APA
Madsbad, S., & Holst, J. J. (2023). Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists. Cardiovascular Research, 119(4), 886-904. https://doi.org/10.1093/cvr/cvac112
Vancouver
Madsbad S, Holst JJ. Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists. Cardiovascular Research. 2023;119(4):886-904. doi:10.1093/cvr/cvac112
BibTeX
@article{Madsbad2023,
author = {Madsbad, Sten and Holst, Jens J},
title = {Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists},
journal = {Cardiovascular Research},
year = {2023},
volume = {119},
number = {4},
pages = {886--904},
doi = {10.1093/cvr/cvac112}
}
EUVIMED